Horizon And Arrowhead To Develop RNAi Therapeutic For Gout
Target Is Xanthine Dehydrogenase, Primary Source Of Serum Uric Acid
Arrowhead and Horizon Therapeutics have inked a deal to develop an investigational RNA interference therapy for uncontrolled gout, under which Arrowhead stands to get $40m upfront and up to $660m in milestones.
You may also be interested in...
Thyroid eye disease drug Tepezza is now expected to generate more than $1.55bn in full year sales, despite missing a full quarter of revenue.
Roche gives back choroideremia candidate to 4D Molecular after reviewing Phase I data, partners on synthetic GI therapy with Synlogic. AbbVie opts to acquire TeneoOne under 2019 agreement.
Analysts have mixed opinions about whether a Phase IIb study of SEL-212, which Selecta recently licensed to Sobi, helps the drug’s commercial potential versus Horizon’s Krystexxa.